| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $5.3M | — | +285.7% |
| SG&A Expense | $11.4M | — | +349.4% |
| Operating Income | -$16.7M | — | -327.2% |
| Net Income | -$125.4M | — | -3241.5% |
| EPS (Basic) | -$2.86 | — | -472.0% |
| EPS (Diluted) | -$2.86 | — | -472.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $32.7M | -60.3% | +88.9% |
| Short-term Investments | $45.4M | — | — |
| Current Assets | $79.1M | -4.8% | +341.3% |
| Total Assets | $94.0M | -4.0% | +186.7% |
| Current Liabilities | $4.5M | +95.7% | +130.2% |
| Total Liabilities | $343.1M | +46.8% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$5.4M | — | -33.3% |
| Investing Cash Flow | -$45.3M | — | — |
| Financing Cash Flow | $1.1M | — | — |
| +453.8% |
| Stockholders' Equity | -$254.0M | -80.5% | -771.4% |